Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines ...

Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

Under the financial terms of the deal, the Wilmington-based biotechnology company will make an upfront payment of $30 million to Genesis Therapeutics, which is eligible to receive up to $885 ...

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...

Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million in an oversubscribed ...

AI biotech startup Genesis Therapeutics entered an agreement with pharmaceutical company Incyte to use Genesis’ AI drug discovery platform, GEMS, to discover small molecule drug candidates ...

Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis’ proprietary AI platform ...